Oura has made women's hormonal health a platform decision, not a product feature, and every competitor now has to respond to that. The ring's new Hormonal Birth Control tracking lets users log contraceptive type and correlate against biometric signals — temperature, sleep, heart rate — through Cycle Insights, as Digital Trends reported. The Menopause Insights feature tracks 22 symptoms drawn from the Menopause Impact Scale. The birth control integration connects directly to Twentyeight Health, a licensed virtual contraception provider, so a user can move from symptom awareness to clinical consultation without leaving the platform.
Competitors cannot replicate that provider connection by shipping a software update.
Apple Watch can track cycle length. Samsung's Galaxy Ring can surface temperature trends. Neither has a licensed provider built into the product. Building one requires regulatory groundwork, clinical partnerships, and liability structures that take years to assemble
The USTA sponsorship, announced alongside these features and running five years, is a brand play. Athlete gifting and sports visibility don't build clinical infrastructure. The Twentyeight Health integration does: it's a licensed medical provider built into the product, not a marketing partnership.
Oura is covering the reproductive lifespan from contraception through menopause with biometric correlation and clinical access at each stage. That's a specific, hard-to-copy category that requires regulatory patience and clinical relationships, not just sensor data.
Apple and Samsung now face a real segmentation problem. Women who want hormonal health tracking have a product built around that need. The others have a feature buried in a health app.